BLS starts FY27 with record revenue and stronger cash generation

Record quarter starts FY27

BLS Pharmaceuticals Limited (ASX:BLS) has begun FY27 with a record quarterly revenue result, posting A$26.7 million in unaudited sales for the three months to 30 September. That was 23% above the previous quarter and 91% higher than Q1 FY26, extending a run of sequential quarterly growth.

The company attributed the result to higher manufacturing volumes across its Australian operations, continued expansion in white-label and contract manufacturing, greater utilisation of its GMP platform and ongoing supply to ADREXpharma in Germany under a two-year agreement. The German supply relationship was part of the A$50 million German supply deal, which earlier coverage identified as a major international contract for BLS.

Cash flow turns positive as investment continues

BLS also reported A$22.4 million in customer cash receipts and A$2.0 million in net operating cash flow, compared with negative operating cash flow of A$4.1 million in Q1 FY26. Cash stood at A$12.7 million at quarter-end, down from neither the source does not say? Wait: 30 June 2026 A$13.3m, so down A$0.6m. We can state it fell from A$13.3m at June.

The operating cash flow result came despite A$2.4 million of investment in the Scotland facility and a further A$0.3 million spent expanding Australian facilities. BLS also paid A$2.3 million in supplier deposits for inventory not yet received. Those commitments mean the quarter's cash generation cannot be viewed in isolation from the spending required to support the company's planned expansion.

Guidance holds after strong first quarter

BLS reaffirmed FY27 revenue guidance of A$105 million to A$115 million, representing growth of 42% to 55% against FY26, alongside an adjusted EBITDA margin target of 23% to 26%. The company said the outlook is underpinned by increased use of existing Australian capacity, international supply agreements, additional pharmaceutical manufacturing customers, growing international activity and progress towards operational status for the Scotland facility.

Inventory was A$17.5 million at 30 September, broadly stable against A$17.8 million at 30 June. BLS said the stock supports forecast customer demand, continuity-of-supply requirements and larger domestic and international purchasing and manufacturing programs. The figures are unaudited, while adjusted EBITDA is a non-IFRS measure and the full-year guidance remains subject to execution and other stated uncertainties.

Scotland facility remains a key execution test

The Scotland project is now one of the clearest operational markers for the remainder of FY27. BLS says it is progressing the facility towards regulatory approval while expanding its broader pharmaceutical manufacturing capabilities; the presentation does not provide a date for approval or commercial operation. Earlier coverage reported that the site was approaching regulatory review, making the next update on inspection, licensing and commissioning more consequential than the quarter's headline revenue alone.

BLS is pursuing a manufacturing platform with stated annual revenue capacity of more than A$250 million at its Brisbane GMP facility. The immediate question is whether customer demand, international supply commitments and new pharmaceutical manufacturing relationships can be converted into revenue at the pace implied by the reaffirmed guidance, without placing disproportionate pressure on inventory, supplier prepayments or cash.